EP1708754A2 - Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb - Google Patents
Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sbInfo
- Publication number
- EP1708754A2 EP1708754A2 EP04803903A EP04803903A EP1708754A2 EP 1708754 A2 EP1708754 A2 EP 1708754A2 EP 04803903 A EP04803903 A EP 04803903A EP 04803903 A EP04803903 A EP 04803903A EP 1708754 A2 EP1708754 A2 EP 1708754A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- imidazoline
- mixture
- solvates
- stereoisomers
- ratios
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Definitions
- the present invention relates to combinations of serotonin reuptake inhibitors (SRIs) and imidazoline agonists as separate chemical units or both properties combined in one molecule and their use for the manufacture of medicaments for the treatment of depression, obsessive compulsive disorders disorders, OCD), obsessive compulsive spectrum disorders (OCSD) and other anxiety disorders.
- SRIs serotonin reuptake inhibitors
- imidazoline agonists as separate chemical units or both properties combined in one molecule and their use for the manufacture of medicaments for the treatment of depression, obsessive compulsive disorders disorders, OCD), obsessive compulsive spectrum disorders (OCSD) and other anxiety disorders.
- Serotonin reuptake inhibitors such as fluoxetine, sertraline, paroxetine, fluvoxamine or citalopram are standard therapeutic agents for the treatment of depression such as unipolar depression, bipolar depression, dysthymia or secondary-occurring depression in connection with physical illnesses, obsessive-compulsive disorder (obsessive-spectrum disorders) e.g. Pigott TA, Seay SM (1999) J Clin Psychiatry 60: 101-106) and other anxiety conditions such as generalized anxiety, post-traumatic stress disorder, social anxiety or panic disorder.
- depression such as unipolar depression, bipolar depression, dysthymia or secondary-occurring depression in connection with physical illnesses, obsessive-compulsive disorder (obsessive-spectrum disorders) e.g. Pigott TA, Seay SM (1999) J Clin Psychiatry 60: 101-106) and other anxiety conditions such as generalized anxiety, post-traumatic stress disorder, social anxiety or panic disorder.
- Imidazoline l 2 agonists such as 2-BFI, LSL 60101, LSL 61122, BU224,
- the first selective Imidazoline I 2 agonist is 2-BFI (2- (2-benzofuranyl) -2- imidazolines) described (eg Lione et al, Br J Pharmacol, 1995, 114:. 412P; Lione et al, Eur J Pharmacol 1996th , 304: 221-229; Coates et al., Bioorg Med Chem Lett 2000, 10: 605-607).
- SRI serotonin reuptake inhibitor
- 2- (2-benzofuranyl) -2-imidazoline (2-BFI) was - as in described below - examined using microdialysis studies and animal models for depression and anxiety.
- a typical animal model for anxiety is the "marble burying test" (e.g. Njung'e and Handley, Br J Pharmacol 1991, 104: 105-112), which has specificity for obsessive-compulsive disorders and obsessive-spectrum disorders.
- the test device consists of a cube-shaped box open at the top, in which 25 clear glass marbles are arranged at regular intervals on a 5 cm high layer of sawdust. Mice are individually placed in the test box for 30 minutes. The number of marbles buried in the sawdust during the test period of 30 minutes serves as a measure of fear. Untreated mice bury most of the marbles in the sawdust, while anxiolytics reduce the number of marbles buried.
- a typical animal model for depression is the "forced swimming test” (RD Porsolt et al., Nature 1977; 266 (5604): 730-732), which is performed on rats.
- This model is based on the behavior known as "behavioral despair", which the animals show in a hopeless situation known to them: if the rats are placed in a container filled with water (usually for 15 minutes) from which they cannot free themselves, after a certain time, stop trying to escape the situation and remain immobile or only make the most necessary swimming movements. If the rats are exposed to this situation again the next day, they recognize the hopelessness of the situation and now remain in immobility for the majority of the time, and the time that the animals spend in immobility during the 5-minute test period (which is considered a surrogate for depression) is used as a measure of depression. Antidepressants shorten this immobility period.
- Fluoxetine (5 mg / kg orally) and 2-BFI (3 and 10 mg / kg orally) are - individually or combined - either after a repeated acute (fluoxetine 24 h, 5 h and 2 h; 2-BFI 24 h, 5 h and 1 h before the start of the test) or according to a subchronic (fluoxetine or 2-BFI once a day for 7 days, on the last day fluoxetine 2 h and 2-BFI 1 h before the start of the test) schedule.
- a repeated acute fluoxetine 24 h, 5 h and 2 h; 2-BFI 24 h, 5 h and 1 h before the start of the test
- subchronic fluoxetine or 2-BFI once a day for 7 days, on the last day fluoxetine 2 h and 2-BFI 1 h before the start of the test
- the present invention thus relates to a substance and / or a mixture of substances which have serotonin reuptake-inhibiting and imidazoline- ⁇ - receptor agonistic properties and / or its Derivatives, stereoisomers and pharmaceutically usable derivatives, including their mixtures in all ratios.
- the present invention relates in particular to a substance which inhibits serotonin reuptake and at the same time agonistically binds to the imidazoline-l 2 receptor.
- the present invention furthermore relates to a substance which inhibits serotonin reuptake and, at the same time, agonistically binds to the imidazoline - ⁇ receptor, and / or a mixture of substances comprising one or more SRI and one or more imidazoline-l 2 agonists, in particular in its capacity as a medicament, as well as corresponding pharmaceutical preparations containing this mixture of substances and possibly other active pharmaceutical ingredients (preferably CNS-active ingredients).
- the mixture of substances or the pharmaceutical preparation contains 2-BFI as SRI fluoxetine and as imidazoline agonist.
- the invention further relates to the use of said substance and / or mixture of substances for the manufacture of a medicament for the treatment or prophylaxis of diseases in which the inhibition of serotonin reuptake and the agonistic binding of active substances to the imidazoline-l 2 receptor to improve the clinical picture leads.
- the diseases are in particular depression, obsessive compulsive disorders (OCD), obsessive compulsive spectrum disorders (OCSD) and anxiety.
- the present invention also relates to a pharmaceutical preparation according to the invention which, in addition to the substance and / or mixture of substances according to the invention, may also contain carriers and / or auxiliaries and — optionally — further active substances, preferably CNS-active substances.
- the medicaments can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active substances.
- the substance and / or the mixture of substances is generally administered in analogy to known preparations, preferably in doses between about 0.1 and 500 mg, in particular between 5 and 300 mg per dosage unit.
- the daily dosage is preferably between about 0.01 and 250 mg / kg, in particular between 0.02 and 100 mg / kg body weight.
- the substance and / or the substance mixture is preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
- the daily dosage is preferably between about 0.02 and 10 mg / kg body weight.
- the specific dose for each particular patient depends on a variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination, combination of drugs and The severity of the disease to which the therapy applies. Oral application is preferred.
- the two components of the mixture of substances can be dosed independently of one another in relation to one another.
- Suitable carrier substances are organic or inorganic substances which are suitable for enteral (for example oral), parenteral or topical application. NEN and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, polyethylene glycols, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, coated tablets, capsules, syrups, juices, drops or suppositories are used in particular for enteral administration, solutions, preferably oily or aqueous solutions, furthermore suspensions, emulsions or implants for parenteral administration, and ointments, creams or powders for topical application.
- the new compounds can also be lyophilized and the resulting lyophilisates used, for example, for the production of injection preparations.
- the specified preparations can be sterilized and / or contain auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colorants, flavorings and / or flavorings. If desired, they can also contain one or more other active ingredients, e.g. one or more vitamins.
- auxiliaries such as lubricants, preservatives, stabilizers and / or wetting agents, emulsifiers, salts for influencing the osmotic pressure, buffer substances, colorants, flavorings and / or flavorings.
- they can also contain one or more other active ingredients, e.g. one or more vitamins.
- a solution of 100 g of a substance and / or substance mixture according to the invention and 5 g of disodium hydrogenphosphate in 3 l of double-distilled water is adjusted to pH 6.5 with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized and sealed sterile. Each injection jar contains 5 mg substance mixture.
- Example A2 suppositories
- Example A3 Solution A solution of 1 prepares g of a material of the invention / or composition, 9:38 g of NaH 2 P0 4 x 2 H 2 O, 28.48 g NaH 2 PO 4 x 12 H 2 O and 0.1 g of benzalkonium chloride in 940 ml twice and distilled water. It is adjusted to pH 6.8, made up to 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.
- Example A4 ointment
- 500 mg of a substance and / or substance mixture according to the invention are mixed with 99.5 g of petroleum jelly under aseptic conditions.
- a mixture of 1 kg of a substance and / or mixture of substances according to the invention, 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of mixture of substances.
- Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and dye.
- a solution of 1 kg of a substance and / or substance mixture according to the invention in 60 l of double-distilled water is filled into ampoules, lyophilized under aseptic conditions and sealed sterile. Each ampoule contains 10 mg substance mixture.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004002638A DE102004002638A1 (de) | 2004-01-19 | 2004-01-19 | Kombinationen von Serotonin-Wiederaufnahme-Hemmern und Imidazolin-I2-Agonisten |
PCT/EP2004/014284 WO2005067969A2 (fr) | 2004-01-19 | 2004-12-15 | Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i2 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1708754A2 true EP1708754A2 (fr) | 2006-10-11 |
Family
ID=34778082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04803903A Withdrawn EP1708754A2 (fr) | 2004-01-19 | 2004-12-15 | Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb |
Country Status (7)
Country | Link |
---|---|
US (1) | US20080027140A1 (fr) |
EP (1) | EP1708754A2 (fr) |
JP (1) | JP4728257B2 (fr) |
AU (1) | AU2004313648B2 (fr) |
CA (1) | CA2553629A1 (fr) |
DE (1) | DE102004002638A1 (fr) |
WO (1) | WO2005067969A2 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1846430T1 (sl) | 2005-02-09 | 2009-08-31 | Basilea Pharmaceutica Ag | Novi makrolidi |
US20100298305A1 (en) * | 2008-11-26 | 2010-11-25 | The United States Government, As Represented By The Department Of Veterans Affairs | Tizanidine for the treatment of post-traumatic stress disorder and nightmares |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914235A (en) * | 1996-10-11 | 1999-06-22 | Eli Lilly And Company | Potentiation of 3 H! 2-(2-benzofuranyl)-2-imidazoline (BFI) binding sites in human tissue by tranylcypromine (TCP) |
WO1999020279A1 (fr) * | 1997-10-17 | 1999-04-29 | Eli Lilly And Company | Potentialisation de produits pharmaceutiques |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
AU4919099A (en) * | 1998-07-11 | 2000-02-01 | University Of Bristol, The | Compounds having activity at imidazoline receptors |
US6068846A (en) * | 1998-08-05 | 2000-05-30 | Melaleuca, Incorporated | Methods and materials for treating depression and mood disorder |
HU0200980D0 (fr) * | 2002-03-14 | 2002-05-29 | Gabor S Pal Dr |
-
2004
- 2004-01-19 DE DE102004002638A patent/DE102004002638A1/de not_active Withdrawn
- 2004-12-15 WO PCT/EP2004/014284 patent/WO2005067969A2/fr active Application Filing
- 2004-12-15 CA CA002553629A patent/CA2553629A1/fr not_active Abandoned
- 2004-12-15 EP EP04803903A patent/EP1708754A2/fr not_active Withdrawn
- 2004-12-15 JP JP2006548147A patent/JP4728257B2/ja not_active Expired - Fee Related
- 2004-12-15 AU AU2004313648A patent/AU2004313648B2/en not_active Ceased
- 2004-12-15 US US10/586,457 patent/US20080027140A1/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO2005067969A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP4728257B2 (ja) | 2011-07-20 |
AU2004313648A1 (en) | 2005-07-28 |
WO2005067969A2 (fr) | 2005-07-28 |
DE102004002638A1 (de) | 2005-08-18 |
CA2553629A1 (fr) | 2005-07-28 |
AU2004313648B2 (en) | 2010-09-30 |
US20080027140A1 (en) | 2008-01-31 |
WO2005067969A3 (fr) | 2007-04-05 |
JP2007520475A (ja) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69710390T2 (de) | Pharmazeutische Zusammensetzungen mit Mirtazapin und einem oder mehreren selektiven Serotonin-Aufnahme Inhibitoren | |
DE60103556T3 (de) | Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten | |
DE69930243T2 (de) | Behandlung iatrogenen und altersbedingten bluthochdruck mit vitamin b6-derivative, und pharmazeutische zusammensetzungen verwendbar dazu | |
DE69034149T2 (de) | Verwendung von Sertralin zur Behandlung von posttraumatischen Stresserkrankungen | |
DE60016602T2 (de) | Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel | |
DE69805202T2 (de) | Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs | |
DE60120104T2 (de) | Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz | |
DE69715899T2 (de) | Zusammensetzungen zur behandlung der peripheren neuropathie, die antidepressiven verbindungen und/oder monoamino-oxidaseinhibitoren und/oder vitamin b12 und/oder neurotransmitter-vorläufer oder induktoren enthalten | |
DE60008374T2 (de) | Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten | |
DE60004348T2 (de) | Kombinierte vorbereitungen, die morpholin anthracyclin und platin derivate | |
AT10974U1 (de) | Verwendung von enantiomer-reinem escitalopram | |
DE69725345T2 (de) | Verwendung von 5-ht4 antagonisten zur überwindung der gastrointestinalen beschädigung, die durch inhibitoren der serotonin-wiederaufnahme hervorgerufen werden | |
DE69824313T2 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
DE10393729T5 (de) | Verfahren zur Behandlung von Emesis | |
DE69129750T2 (de) | Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung | |
EP1461042B1 (fr) | Utilisation de desoxypeganine pour le traitement de la depression clinique | |
DE2362123A1 (de) | Pharmazeutische zubereitungen | |
DE60217870T2 (de) | Verwendung von 2- 5-(4-fluorphenyl)-3-pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze | |
EP1513533A2 (fr) | Combinaison d'agents actifs pharmaceutiques et utilisation | |
DE60114419T2 (de) | Neue verwendung von (r)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)-chromane und ihrer physiologisch verträglichen salze | |
EP1708754A2 (fr) | Association d'inhibiteurs de reprise de serotonine et d'agonistes d'imidazoline-i sb 2 /sb | |
DE60100431T2 (de) | Arzneistoffkombination zur behandlung von kopfschmerzen mit mirtazapine und paracetamol oder nicht-steroiden entzündungshemmenden mitteln | |
DE60220825T2 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
DD297557A5 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
DE10318714B4 (de) | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20060519 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR LV MK YU |
|
DAX | Request for extension of the european patent (deleted) | ||
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
17Q | First examination report despatched |
Effective date: 20091201 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20120703 |